Commentary on Brose et al. (2015): Protecting individual and public health by regulating electronic cigarette nicotine delivery

Melissa D. Blank1,* and Thomas Eissenberg2

1Department of Psychology, West Virginia University, Morgantown, WV, USA
2Department of Psychology and Center for the Study of Tobacco Products, Virginia Commonwealth University, Richmond, VA, USA

Brose and colleagues [1] used a national data set from Great Britain to demonstrate that, in current tobacco cigarette smokers, daily but not non-daily electronic cigarette (e-cig) use shows a significant association with increased tobacco smoking cessation attempts and reductions in smoking behavior. However, e-cig use was not shown in this study to be associated significantly with tobacco smoking cessation. Taken together, this new study [1] and the extant literature (e.g. [2, 3]) provide little empirical support for the contention that e-cig use leads reliably to smoking cessation for the majority of users.

Tobacco cigarette smokers self-administer the stimulant drug nicotine with every puff that they inhale, and most of them are dependent on the drug [4]. This dependence makes cessation difficult, in part because of an aversive abstinence syndrome that occurs during a cessation attempt (e.g. [5]). Nicotine replacement medications act by delivering nicotine to the user and thus suppressing at least some aversive abstinence symptoms: the more nicotine, the greater the symptom suppression (e.g. [6]). E-cigs are not marketed as medications in many countries, but are a class of products that use an electric heater to aerosolize a liquid that usually contains some combination of propylene glycol, vegetable glycerin, flavorants and nicotine. Despite not being marketed as medications, many smokers are attempting to quit tobacco cigarettes by using e-cigs daily; however, there is little information regarding the long-term health risks associated with daily e-cig use. Putting aside that concern, if daily e-cig use is to lead to smoking cessation for the majority of users, then e-cigs will probably need to deliver nicotine in doses necessary to suppress abstinence symptoms as effectively as a tobacco cigarette. Unfortunately, there is wide variability in e-cig nicotine delivery: 10 puffs from an e-cig may, for example [7], or may not [8], result in reliable nicotine delivery to the user’s blood. Differences across studies can be explained by a combination of factors, including characteristics of the e-cig device and liquid, as well as user behavior [9]. Those e-cig device/liquid combinations that are most likely to lead to smoking cessation may well be those that approximate the nicotine delivery profile of a tobacco cigarette (e.g. [10]).

*Correspondence: Melissa D. Blank, Department of Psychology, 53 Campus Drive, 2214 Life Science Building, Morgantown, WV 26506-6040, USA. mdblank@mail.wvu.edu.

Declaration of interests
None.
Strangely, e-cigs that are far less effective at delivering nicotine continue to be marketed to smokers. For instance, 50 puffs from either of two Blu e-cig (Lorillard, Inc., Greensboro, NC, USA) models that are currently available on the US market deliver 23–53% less nicotine to the user relative to approximately 10 puffs from a conventional tobacco cigarette [11], yet Blu e-cig brands are rated as the most popular among US young adults [12]. Perhaps relatedly, more than 80% of all US televised e-cig advertisements geared toward youth and young adults were for Blu e-cigs [13], and 90% of all US advertising expenditures for e-cig brands have been for Blu E e-cigs [14]. The fact that some e-cigs that are advertised to youth and young adults actively also deliver very little nicotine is reminiscent of so-called ‘starter products’ common in the smokeless tobacco arena [15]. Starter products allow nicotine-naive users to self-administer low doses of nicotine without experiencing drug-mediated adverse side effects and then, as tolerance develops, these users can ‘graduate’ to products that deliver increasing doses of the drug (e.g. [15]). Public health policy-makers may want to recall this industry strategy when considering regulatory action regarding e-cigs.

Further complicating this issue is that at least 466 distinct brands of e-cigs are marketed currently [16], some by major tobacco companies. Tobacco companies in particular may be interested in smokers who purchase an e-cig as part of a smoking cessation strategy but, as Brose et al.’s [1] data suggest, ultimately do not quit smoking, perhaps because the e-cig they bought underperforms a tobacco cigarette in terms of nicotine delivery to the user. Under this scenario, the tobacco company that sells the under-performing product profits from sales of e-cigs and tobacco cigarettes, while the smoker who purchased the under-performing product in addition to tobacco cigarettes continues to be at risk for tobacco-caused disease and death.

Much has been written about the potential for e-cigs to provide public health benefit through a dramatic reduction in tobacco cigarette smoking (e.g. [17]). This potential benefit may require science-based regulatory intervention to ensure that e-cigs deliver nicotine effectively to cigarette smokers, while avoiding e-cig-induced nicotine dependence in non-smokers via the starter product strategy. Also, some e-cig device/liquid combinations on the market today may deliver nicotine more effectively than the highly addictive tobacco cigarette [18]; there is no clear public health rationale for such products, and regulation can help to limit their availability. Relevant foci for regulatory intervention that address drug delivery include product characteristics [9] and nicotine flux [19]. Without meaningful, science-based regulation, there may be many future opportunities to report, as do Brose et al. [1], that e-cigs are not effective tools for helping the majority of smokers to quit using lethal tobacco cigarettes.

Acknowledgments

T.E.’s research is supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number P50DA036105 and the Center for Tobacco Products of the US Food and Drug Administration. The content is solely the responsibility of the authors and does not necessarily represent the views of the NIH or the FDA. M.D.B.’s research is supported by the National Institute on Drug Abuse of National Institutes of Health under Award Number R03DA037583; USDHHS Centers for Disease Control and Prevention U48 DP001921 and West Virginia University Senate Research Award.
References


